Andrea Lobo,  —

Ad Scientiam has launched a program to develop and validate new digital biomarkers for self-assessing patients with generalized myasthenia gravis (gMG). The launch was announced on Rare Disease Day, Feb. 28, and is supported by Alexion, AstraZeneca Rare Disease. “Easy-to-use digital tools have the potential to generate reliable…

Thymus removal surgery is generally safe for the majority of elderly people who have myasthenia gravis (MG), a study in China found. In fact, all patients ages 65 and older in the study were safely discharged and did not need to stay longer in the hospital. Nonetheless, according to…

Post-operative myasthenic crisis is a dangerous complication after thymus removal surgery for people with myasthenia gravis (MG) who had no tumor in their thymus, according to researchers who set out to identify factors that increase this risk in a recent study. They determined risk factors to be: having a…

A protein called CD59 might protect the neuromuscular junction — the place where nerve cells come into contact and communicate with muscle cells — from the harmful action of the body’s immune system in myasthenia gravis (MG) patients, a study in Japan suggests. “CD59 overexpression might be required for…

The presence of anti-titin antibodies, a type of blood protein, in patients with thymoma-associated myasthenia gravis (MG) is related to more frequent hospitalizations, a study in South Korea has found. Thymoma is a type of tumor occurring in the thymus gland, a small organ in the chest that…

Intravenous immunoglobulin therapy was not effective at reducing the daily dose of corticosteroids for treating myasthenia gravis (MG), a multicenter Phase 2 trial shows. “These results suggest that immunomodulation alone was insufficient to facilitate dose reduction,” the researchers wrote. The trial results were reported in the study, “…